Related coverage linked through entity extraction aliases.
May 12, 2026
BrightGene Bio-Medical reported Phase III data for BGM0504 showing 19.3% mean weight reduction and improvements in blood pressure, lipids and uric acid. The data highlighted GIP as a key variable in broader metabolic management.
May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Apr 28, 2026
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Apr 08, 2026
Researchers have used a machine learning model called AI-IR to demonstrate that insulin resistance is a risk factor for 12 types of cancer. The tool analyzes nine clinical parameters from standard health checkups to predict insulin resistance at population scale. This provides the first large-scale evidence linking insulin resistance to multiple cancers.
Mar 15, 2026
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Mar 09, 2026
Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial evaluating enobosarm combined with semaglutide for weight loss in older patients with obesity. The study will assess enobosarm's ability to preserve lean mass and physical function while augmenting fat loss.
Mar 05, 2026
Semaglutide reduced osteoarthritis progression in obese mice through metabolic reprogramming of cartilage cells, independent of weight loss effects, according to research published in Cell Metabolism.
Mar 04, 2026
A new study suggests 7 hours and 18 minutes of sleep may be optimal for reducing insulin resistance risk. The research found an inverted U-shaped relationship between sleep duration and glucose metabolism, with weekend catch-up sleep showing mixed effects.
Mar 01, 2026
Three GLP-1 weight-loss drugs—semaglutide, tirzepatide and retatrutide—reduced weight and improved metabolic health in mice lacking the MC4R gene, offering potential treatment for rare genetic obesity.
Feb 18, 2026
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
Feb 17, 2026
Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.
Feb 16, 2026
Researchers used a machine-learning tool to analyze 500,000 UK Biobank participants, providing the first population-scale evidence that insulin resistance is a risk factor for 12 types of cancer.
Feb 13, 2026
Researchers at the University of Pittsburgh School of Medicine discovered that protecting VAT macrophages in visceral fat tissue can improve insulin sensitivity, offering a potential new therapeutic approach for type 2 diabetes.
